INTEGRATED FILING — Other than Banks



General information about company

Scrip code 000000
NSE Symbol UNIHEALTH
MSEI Symbol NOTLISTED
ISIN INE0PRF01011
Name of Company Unihealth Hospitals Limited
Type of company SME
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 23-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 14-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Half Yearly
Reporting Quarter Yearly
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Healthcare
Start date and time of board meeting 23-May-2025   14:30:00
End date and time of board meeting 23-May-2025   15:37:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? No
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? No
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
(III) Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? No
Latest Date on which RPT policy is updated
Indicate Company website link for updated RPT policy of the Company
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
NA


Financial Results — Other than Bank
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Oct-2024 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Revenue From Operations
Revenue from operations 20022000 35610000
Other income 18023000 33058000
Total Income 38045000 68668000
2 Expenses
(a) Cost of materials consumed 0 0
(b) Purchases of stock-in-trade 5884000 5884000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0 0
(d) Employee benefit expense 8541000 16525000
(e) Finance costs 171000 293000
(f) Depreciation and amortisation expense 1486000 2823000
(g) Other Expenses
1 Other Expenses 5344000 11048000
Total other expenses 5344000 11048000
Total expenses 21426000 36573000
3 Profit before exceptional and extraordinary items and tax 16619000 32095000
4 Exceptional items 0 0
5 Profit before extraordinary items and tax 16619000 32095000
6 Extraordinary items 0 0
7 Profit before tax 16619000 32095000
8 Tax Expense
Current tax 4905000 9007000
Deferred tax -348000 -249000
Total tax expenses 4557000 8758000
9 Net Profit Loss for the period from continuing operations 12062000 23337000
10 Profit (loss) from discontinuing operations before tax 0 0
11 Tax expense of discontinuing operations 0 0
12 Net profit (loss) from discontinuing operation after tax 0 0
13 Profit (loss) for period before minority interest 12062000 23337000
14 Share of profit (loss) of associates
15 Profit (loss) of minority interest
16 Net profit (Loss) for the period 12062000 23337000
17 Details of equity share capital
Paid-up equity share capital 154000000 154000000
Face value of equity share capital 10 10
18 Reserves excluding revaluation reserve 514071000
19 Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.79 1.52
Diluted earnings (loss) per share from continuing and discontinued operations 0.79 1.52
20 Debt equity ratio 4.0E-4 4.0E-4
21 Debt service coverage ratio 8.0E-4 0.0023
22 Interest service coverage ratio 0.9846 1.1072
23 Disclosure of notes on financial results Textual Information(1)


Text Block
Textual Information(1) 1. As per MCA Notification dated 16th February 2015, companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adopton of IND AS. As the Company is covered under the exempted category, it has not adopted IND AS for the preparation of financial results. 2. The Statutory Auditors of the Company have carried out audit of the financial results for the Half Year ended on March 31, 2025 in compliance with terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements ) Regulations ,2015. The above financial results have been audited and recommended by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 23rd May, 2025. 3. Figures for the previous periods /year have been regrouped ,restated and /or reclassified wherever considered necessary to make them comparable to the current periods /presentation. 4. The aforesaid results have been filed with Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are also available on the Stock Exchanges websites and on the website of the Company. 5. The company has issued and alloted 42,84,000 equity shares of Rs.10 each at a premium of Rs.122 per share on 15/09/2023 through initial public offer as per section 52 of companies act, 2013, aggregating to Rs 5654.88 lakhs and net issue expenses Rs 777.70 lakhs has been adjusted against securities premium during previous year 2023-24. 6. The Company is not a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P /2018/144 dated 26th November, 2018. 7. There are no investors complaints pending as on 31st March, 2025. 8. The figures for half year ended 31st March, 2025 are the balancing figures between the audited figures in respect of Financial Year 2024-25 and the published unaudited figures of the Half Year ended September 30, 2024, which were subject to limited review. 9. EPS for half year ended 31st March 2024 is not annualised and arrived at after considering IPO equity shares (42,84,000) issued on 15th September 2023. 10. The name of the company has been changed from Unihealth Consultancy Limited to Unihealth Hospitals Limited vide MCA certificate of Incorporation dated 14th October, 2024. 11. A wholly owned subsidiary company namely Unihealth Holding Limited of the company was incorporated in Mauritius on 7th May, 2024. 12. UMC Global Health Ltd (Nigeria), which was previously a joint venture, has now been converted into a subsidiary company by virtue of acquisition of additional shares through right issue allotted on 30th September, 2024. 13. Pursuant to a resolution passed by Board of Directors of the company on 06th May 2024,the Company has approved to become first subscriber of Memorandum of Association of UMC Hospitals Private Limited by subscribing for 1,52,000 no. of equity shares (80% of shareholding, making it a Subsidiary of the Company) on 22nd May, 2024, amounting to Rs.15,20,000. Payment for the said subscription was effected on 05th July, 2024. 14. The proceeds from the Equity shares IPO issued during FY 23-24 was amounting to Rs 5654.88 lakhs. The object and proposed utilization of IPO Proceeds and amount utilized as on March 31, 2025 is as under:- ( amount in Lakhs) Object Proposed Utilization Amount Utilized Investment in our joint venture, Victoria Hospital Limited (VHL), Kampala, Uganda for funding its capital expenditure 1700.00 1700.00 requirements for proposed expansion and working capital requirements of VHL Investment in our joint venture, UMC Global Health Limited (UMCGHL), Nigeria for funding its capital expenditure requirements 460.00 281.44 for proposed expansion Investment in our subsidiary, Biohealth Limited (BL), Tanzania 237.50 237.50 for funding its capital expenditure requirements for proposed expansion* Investment in our subsidiaries UMC Hospitals Private Limited (India) 1350.00 1350.00 and in Unihealth Holdings Limited (Mauritius) to support expansion and acquisition of projects across India and Africa* General Corporate Purpose 1093.08 1093.08 Issue Expenses 814.30 814.30 * The original object as disclosed in the offer document was further altered by passing a resolution to vary the utilisation of proceeds raised by the Company through an initial public offering of equity shares (the 'IPO') made in pursuance of the Prospectus dated September 14, 2023 (the 'Prospectus') and reallocate the unutilized proceeds for the objects as set out in the Postal Ballot Notice, have been passed with requisite majority on Wednesday, June 26, 2024. Out of initial proposed amount i.e. Rs. 1587.50 Lakhs, Rs.1350 Lakhs were reallocated for investing as equity and debt in UMC Hospitals Private Limited, a subsidiary of the Company in India and in Unihealth Holdings Limited, the wholly owned subsidiary of the Company in Mauritius, to support expansion and acquisition of projects across India and Africa, in furtherance of the current objects of the Company.


Remarks
20 Debt equity ratio
21 Debt service coverage ratio
22 Interest service coverage ratio Because of Decrease in Finance Cost


Cash flow statement — indirect
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
1 Statement of cash flows
Cash flows from used in operating activities
Profit before extraordinary items and tax 32095000
2 Adjustments for reconcile profit (loss)
Adjustments to profit (loss)
Adjustments for finance costs 293000
Adjustments for depreciation and amortisation expense 2823000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for unrealised foreign exchange losses gains 4519000
Adjustments for dividend income 0
Adjustments for share-based payments 0
Other adjustments for which cash effects are investing or financing cash flow -27918000
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items 0
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments to profit (loss) -20283000
3 Adjustments for working capital
Adjustments for decrease (increase) in inventories 0
Adjustments for decrease (increase) in trade receivables -2994000
Adjustments for decrease (increase) in other current assets 3376000
Adjustments for increase (decrease) in trade payables 1009000
Adjustments for increase (decrease) in other current liabilities 1548000
Adjustments for provisions 0
Total adjustments for working capital 2939000
Total adjustments for reconcile profit (loss) -17344000
Net cash flows from (used in) operations 14751000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 9007000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities before extraordinary items 5744000
Proceeds from extraordinary items 0
Payment for extraordinary items 0
Net cash flows from (used in) operating activities 5744000
4 Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 243789000
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property plant and equipment 0
Purchase of property plant and equipment 3410000
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 27918000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Proceeds from government grants 0
Net cash flows from (used in) investing activities before extraordinary items -219281000
Proceeds from extraordinary items 0
Payment for extraordinary items 0
Net cash flows from (used in) investing activities -219281000
Cash flows from used in financing activities
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 0
Repayments of borrowings 0
Dividends paid 0
Interest paid 0
Income taxes paid (refund) 0
Other inflows (outflows) of cash -11258000
Net cash flows from (used in) financing activities before extraordinary items -11258000
Proceeds from extraordinary items 0
Payment for extraordinary items 0
Net cash flows from (used in) financing activities -11258000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes -224795000
6 Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents -224795000
Cash and cash equivalents cash flow statement at beginning of period 266429000
Cash and cash equivalents cash flow statement at end of period 41634000


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Equity and liabilities
1 Shareholders' funds
Share capital 154000000
Reserves and surplus 514071000
Money received against share warrants 0
Total shareholders' funds 668071000
2 Share application money pending allotment 0
3 Deferred government grants 0
4 Minority interest
5 Non-current liabilities
Long-term borrowings 7800000
Deferred tax liabilities (net) 0
Foreign currency monetary item translation difference liability account 0
Other long-term liabilities 0
Long-term provisions 2616000
Total non-current liabilities 10416000
6 Current liabilities
Short-term borrowings 18751000
Trade Payables
(A) Total outstanding dues of micro enterprises and small enterprises 1119000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 172000
Total Trade payable 1291000
Other current liabilities 3128000
Short-term provisions 2583000
Total current liabilities 25753000
Total equity and liabilities 704240000
Assets
1 Non-current assets
i Property, Plant and Equipment and Intangible assets
Property, Plant and Equipment 31090000
Producing properties
Intangible assets 373000
Preproducing properties
Property, Plant and Equipment capital work-in-progress
Intangible assets under development or work-in-progress
Total Property, Plant and Equipment and Intangible assets 31463000
ii Non-current investments 304973000
v Deferred tax assets (net) 395000
vi Foreign currency monetary item translation difference asset account
vii Long-term loans and advances 259316000
viii Other non-current assets 527000
Total non-current assets 596674000
Current assets
Current investments 0
Inventories 0
Trade receivables 29072000
Cash and cash equivalents 41634000
Bank balance other than cash and cash equivalents 0
Short-term loans and advances 666000
Other current assets 36194000
Total current assets 107566000
Total assets 704240000
Disclosure of notes on assets and liabilities


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Oct-2024 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets
Net Segment Asset
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities
Net Segment Liabilities
Disclosure of notes on segments




Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 G P Kapadia & Co Yes 31-Jan-2027


Financial details
Sr. Particulars Audited Figures (as reported before adjusting for qualifications) Adjusted Figures (audited figures after adjusting for qualifications)
1 Turnover / Total income
2 Total Expenditure
3 Net Profit/(Loss)
4 Earnings Per Share
5 Total Assets
6 Total Liabilities
7 Net Worth


Signatories details

Name of CEO / Managing director
Name of CFO
Name of audit committee chairman
Name of statutory auditor
Name of other signatory, if any, with designation
Place
Date


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)
Mode of Fund Raising Public Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 15-Sep-2023
Amount Raised 565488000
Report filed for Quarter ended 31-Mar-2025
Monitoring Agency Not Applicable
Monitoring Agency Name, if applicable
Is there a Deviation / Variation in use of funds raised Yes
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders Yes
If Yes, Date of shareholder Approval 26-Jun-2024
Explanation for the Deviation / Variation The Company vide its Prospectus dated September 14, 2023 (“Prospectus”) had raised Rs. 5654.88 lakhs from the initial public offer of its equity shares (the ‘IPO’). The net proceeds from the IPO were Rs. 4840.58 lakhs /- (hereinafter referred to as “IPO Proceeds”). The Equity shares of the Company got listed on the SME Segment of National Stock Exchange of India Limited (“NSE”) on September 21, 2023. The Board of directors by a resolution dated 23 rd May, 2024 passed at its meeting, proposed to vary the objects for utilisation of proceeds raised by the Company through the IPO and reallocate the unutilized proceeds, which was approved by the shareholders of the Company vide Special resolution passed through postal ballot on June 26, 2024. The details of variation of objects and justification for the same is as under: In line with the Company’s vision of expanding its commissioned bed strength by setting up and/or acquiring tertiary care and/or multi-specialty and/or super-specialty hospitals in key high growth countries of Africa as well as in India, the Company has been exploring possible opportunities for probable acquisitions and collaborations. Following comprehensive and detailed market assessment and study, the Company opined that investments in the Indian healthcare sector are likely to be of strategic benefit for the Company’s growth plans on an immediate basis. In furtherance to the same, UMC Hospitals Private Limited had been incorporated by the Company as its subsidiary, to set up, acquire operations and enter into management contracts for tertiary care hospitals in India. The Company, via UMC Hospitals Private Limited, intends to add a capacity of 150 to 250 commissioned beds across one or more tertiary care hospitals in India under its operational management in the coming 24-36 months. In line with the Company’s proposed plans to establish a pan-African presence and expand its existing bed capacity across Africa from 200 tertiary care beds to more than 500 commissioned beds in the coming 36 months, the Company had incorporated a wholly owned subsidiary, Unihealth Holdings Limited, in Mauritius. The said subsidiary intends to make investments to acquire as well as invest into setting up of facilities in line with the Company’s vision and growth plans, in key target countries of Africa. In furtherance of the same, the Company intends to invest Rs. 1350 lakhs of the unutilised issue proceeds as equity capital and debt into UMC Hospitals Private Limited (India) and Unihealth Holdings Limited (Mauritius), to provide these companies with the required funds for probable investments to acquire and/or invest into setting up of the intended facilities in India and across Africa, an initiative that has necessitated the Company to vary the utilisation of proceeds of the IPO and reallocate the unutilized proceeds. The Board considers it prudent to re-classify and extend the unutilized amount towards investment in the Company’s other subsidiaries to lead to optimum utilization of IPO proceeds and maximize the return on investment for members of the Company, ensuring future growth of the Company.
Comments of the Audit Committee after review None
Comments of the auditors, if any None
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Investment in our joint venture, Victoria Hospital Limited (VHL), Kampala, Uganda for funding its capital expenditure requirements for proposed expansion and working capital requirements of VHL No Modification 170000000 0 170000000 0
2 Investment in our joint venture, UMC Global Health Limited (UMCGHL), Nigeria for funding its capital expenditure requirements for proposed expansio No Modification 46000000 0 28144000 0 178.56 Unutilized Funds
3 Investment in our subsidiary, Biohealth Limited (BL), Tanzania for funding its capital expenditure requirements for proposed expansion As per the Prospectus, Rs. 1,587.50 lakhs was originally allocated to Biohealth Limited (BL), Tanzania for funding its capital expenditure. Out of this unutilized amount, Rs. 1,350 lakhs has now been reallocated to our subsidiaries, UMC Hospitals Private Limited (India) and Unihealth Holdings Limited (Mauritius) to support expansion and acquisition of projects across India and Africa 158750000 23750000 23750000 0
4 NA Investment in our subsidiaries namely UMC Hospitals Private Limited (India) and in Unihealth Holdings Limited (Mauritius) to support expansion and acquisition of projects across India and Africa 0 135000000 135000000 0 Shareholders approved the said reallocation of unutilized proceeds of Rs. 1,350 lakhs for the modified objects by passing special resolution through Postal Ballot on June 26, 2024 & the said amount has been allocated to them
5 General Corporate Purpose No Modification 109308000 0 109308000 0
6 Issue Expenses No Modification 81430000 0 81430000 0


Signatory Details
Name of signatory Binita Patel
Designation of person Company Secretary and Compliance Officer
Place Mumbai
Date 23-May-2025


Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity /subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
Total value of transaction during the reporting period





Format for Disclosing Outstanding Default on Loans and Debt Securities
Sr. No. Particulars Amount Remarks
1. Loans / revolving facilities like cash credit from banks / financial institutions
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
2. Unlisted debt securities i.e. NCDs and NCRPS
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
3. Total financial indebtedness of the listed entity including short-term and long-term debt